Our work also shows that RPL11-mediated nucleolar stress response is crucial for sensitivity to topoisomerase inhibitors, suggesting that RPL11 expression may be a potential biomarker for predicting topoisomerase inhibitor sensitivity in cancer. The gene discussed is RPL11; the disease is cancer.